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Background
The efficacy of montelukast in the treatment of asthma
has been demonstrated in numerous controlled clinical
trials. The aim of this study was to assess the real-life
effectiveness of montelukast administered as monotherapy
or in combination with current ICS in children with
uncontrolled asthma.
Methods
Twelve-week open-label, phase IV, multicenter, prospec-
tive cohort study. Eligible patients included children aged
2-14 years diagnosed with asthma for =6 months who
were: (i) uncontrolled as per the Canadian Asthma
Consensus Guidelines, and; (ii) either untreated, using
a short-acting ß2–agonist as-needed or using any dose
ICS. In this analysis, patients with Asthma Control
Questionnaire (ACQ) score >0.75 were included. Patients
6-14 and 2-5.9 years old were treated once-daily with
montelukast 5mg and 4mg, respectively. Primary outcome
measure was the proportion achieving asthma control
(ACQ=0.75). Secondary outcomes were the absolute
change in ACQ and in the Pediatric Asthma Caregiver’s
Quality of Life Questionnaire (PACQLQ) over time.
Results
Among the 328 patients included, 76 (23.2%) were treated
with montelukast monotherapy and 252 (76.8%) with
montelukast combined with ICS. By 4 weeks of treatment
61.3% and 52.9% of patients in the monotherapy and com-
bination group, respectively, achieved asthma control.
These proportions increased to 75.0% and 70.9%,
respectively, at week-12. Clinically and statistically
(P<0.001) significant improvements were observed in
ACQ (monotherapy: mean (SD) of 1.67 (0.69) at baseline
and 0.50 (0.52) at week-12; combination therapy: 2.02
(0.83) and 0.64 (0.86), respectively) and PACQLQ (mono-
therapy: mean (SD) of 5.34 (1.14) at baseline and 6.51
(0.85) at week-12; combination therapy: 4.42 (1.35) and
6.21 (1.03), respectively) in both patient subgroups. After a
12-week montelukast add-on therapy, 22.6% of patients
reduced their ICS dosage.
Conclusions
Montelukast as monotherapy or in combination with ICS
represents an effective treatment strategy for achieving
asthma control in pediatric patients and improving
caregivers’ quality of life.
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